Stay updated with breaking news from Nasdaq Fold. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Amicus Therapeutics, Inc. (NASDAQ:FOLD – Get Rating) CFO Daphne Quimi sold 4,396 shares of the company’s stock in a transaction that occurred on Friday, June 17th. The stock was sold at an average price of $9.00, for a total transaction of $39,564.00. Following the completion of the sale, the chief financial officer now directly owns […]
Amicus Therapeutics, Inc. (NASDAQ:FOLD – Get Rating) CEO John F. Crowley sold 11,346 shares of the company’s stock in a transaction dated Friday, June 3rd. The stock was sold at an average price of $8.00, for a total value of $90,768.00. Following the completion of the sale, the chief executive officer now owns 932,807 shares […]
Analysts predict that Amicus Therapeutics, Inc. (NASDAQ:FOLD – Get Rating) will announce sales of $87.77 million for the current quarter, according to Zacks. Three analysts have made estimates for Amicus Therapeutics’ earnings, with the highest sales estimate coming in at $89.30 million and the lowest estimate coming in at $85.01 million. Amicus Therapeutics reported sales […]
Amicus Therapeutics, Inc. (NASDAQ:FOLD – Get Rating) CEO John F. Crowley sold 2,214 shares of the business’s stock in a transaction on Monday, April 18th. The shares were sold at an average price of $8.04, for a total transaction of $17,800.56. Following the sale, the chief executive officer now owns 974,221 shares of the company’s […]
Equities analysts expect Amicus Therapeutics, Inc. (NASDAQ:FOLD – Get Rating) to announce earnings of ($0.26) per share for the current quarter, according to Zacks. Three analysts have made estimates for Amicus Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.17) and the lowest estimate coming in at ($0.30). Amicus Therapeutics posted earnings of […]